New patent lawsuit: Walgreen Co. v. Allergan, Inc. – Drug patent: 8,685,930

A new lawsuit citing drug patent 8,685,930 has been filed. The small molecule drug covered by this patent is RESTASIS. See more details at Walgreen Co. v. Allergan, Inc.. For…
The post New patent lawsuit: Walgreen Co. v. Allergan, Inc. – Dr…


New patent expiration for LILLY drug CIALIS

Annual Drug Patent Expirations for CIALIS Cialis is a drug marketed by Lilly and is included in one NDA. It is available from eight suppliers. There are four patents protecting…
The post New patent expiration for LILLY drug CIALIS appeared first …


New patent expiration for Eli Lilly drug ADCIRCA

Annual Drug Patent Expirations for ADCIRCA Adcirca is a drug marketed by Eli Lilly Co and is included in one NDA. It is available from three suppliers. There are three…
The post New patent expiration for Eli Lilly drug ADCIRCA appeared first on D…


Patents for Combination Products: Challenges and Opportunities

Combination products offer companies new directions for drug patent innovation. Medicine has become more personalized over the past generation, and this has affected the drug patent system. One major trend…
The post Patents for Combination Produc…


How Pharmaceutical Blockchain Technology Challenges Can Be Overcome

By Ed Lamb, DrugPatentWatch Writer Pilot projects are underway, but regulatory and stakeholder buy-in concerns remain When pharmaceutical supply chain stakeholders met recently to discuss applications for blockchain technology, they…
The post How…


Get single drug patent reports at DrugPatentWatch

Many readers have been asking for a simple way to get information on just a few drugs. While we do offer short-term three-month subscriptions, there is still a demand for…
The post Get single drug patent reports at DrugPatentWatch appeared first …


Estimated costs of production and potential prices for the WHO Essential Medicines List

This article was originally published by Andrew M Hill, Melissa J Barber, and Dzintars Gotham in BMJ Global Health Jan 2018, 3 (1) e000571 under a Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license. Abstract Introduction There are persi…


Decision-making in product portfolios of pharmaceutical research and development – managing streams of innovation in highly regulated markets

This article was originally published by Antti Jekunen in Drug Des Devel Ther. 2014; 8: 2009–2016 under a Creative Commons Attribution – Non Commercial (unported, v3.0) License. Abstract Decision-making is a core function…
The post Decision-makin…


Biobetters, Supergenerics Hold Many Advantages for Pharma Companies

By Larry Ramer, DrugPatentWatch writer A growing number of pharmaceutical companies are looking to simultaneously benefit from the low costs of developing generic treatments and the increased market share and…
The post Biobetters, Supergenerics H…


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: